Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

International journal of oncology

Volumn 20, Issue 4, 2002, Pages 745-752

  Wang, Hui ^a   Wang, Shuyi ^a   Nan, L ^a   Yu, Dong ^a   Agrawal, Sudhir ^a   Zhang, Ruiwen ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA TOPOISOMERASE; DRUG DERIVATIVE; IRINOTECAN; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; COLON TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; MUTATION; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036548741     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.20.4.745     Document Type: Article

References (0)